Stifel raises Edwards Lifesciences stock to buy, target to $90
Stifel analysts upgraded Edwards Lifesciences (NYSE:EW) stock from Hold to Buy, citing potential growth acceleration in the Transcatheter Aortic Valve Replacement (TAVR) market. The firm also ...
Edwards Lifesciences upgraded to Buy from Hold at Stifel
Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR, ...